Amgen, Lumakras

FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation
The Food and Drug Administration approved Amgen Inc ‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) for KRAS G12C-mutated metastatic colorectal cancer (mCRC), who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapy .
Amgen's Lumakras+Vectibix Combo Gets FDA Approval For Metastatic Colorectal Cancer Treatment
Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination
Looking Beyond Obesity, Amgen Wins Colorectal Cancer Expansion for Lumakras
The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic colorectal cancer, but in its approval announcement, the FDA pointed to significant improvements in progression-free survival,
US FDA approves Amgen's colorectal cancer therapy
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation. Amgen's Lumakras in combination with Vectibix was approved to treat adult patients whose cancer has spread to other parts of the body despite receiving chemotherapy,
FDA approves new colorectal cancer treatment
THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $144.8 billion, has received FDA approval for LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) to treat adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC).
Here’s Why Amgen Inc. (AMGN) Is Among the Highest Yielding Dividend Stocks In the Dow
We recently compiled a list of the 13 Highest Yielding Dividend Stocks in the Dow. In this article, we are going to take a ...
FierceBiotech2d
Fierce Biotech Layoff Tracker 2025: Notch reduces staff; Apellis cuts 40 workers
We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...
Zacks.com on MSN2d
Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Amgen (AMGN) closed the most recent trading day at $272.11, moving +0.99% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1% for the day. Meanwhile, ...
BioPharma Dive5d
JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning
Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.
Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while - ...
FiercePharma3d
Gilead's Kite taps longtime Amgen alum as new global commercial head
Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...
Unpacking the Latest Options Trading Trends in Amgen
Today, Benzinga's options scanner spotted 11 options trades for Amgen. This isn't normal. The overall sentiment of these ...
Durham biotech pursuing 'undruggable' diseases names new CEO
Ribometrix, a spinout of UNC-Chapel Hill, has named William Marshall as its new CEO, succeeding former chief executive ...